Categories: News

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11

Presentation and conference call will include topline data from all cohorts

The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy

LA JOLLA, Calif.., June 03, 2021 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will host a conference call on Friday, June 11, 2021, at 8:00 am ET, following an oral presentation of data from the EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) at EHA2021 Virtual Congress.

Presenters include:

  • Dolca Thomas, M.D., Chief Medical Officer
  • Steve Connelly, Ph.D., Chief Scientific Officer
  • Bruce Steel, Chief Executive Officer

The presentations will be followed by Q&A with management.

Details for the conference call will be provided the morning of Friday, June 11. A live webcast of the event will be available on the company’s website and a replay will be available for 90 days on the Events & Presentations page of the Investor Relations section of the company’s website at https://ir.equilliumbio.com/events-and-presentations.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com

Media Contacts
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Staff

Recent Posts

Nashville-Based ObjectiveHealth, QualDerm Partners Expand Partnership to Increase Care Options for Patients

NASHVILLE, Tenn.--(BUSINESS WIRE)--#aesthetics--ObjectiveHealth, a Nashville-based integrated research and technology platform company, announced today that it…

2 hours ago

Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leading AI-driven health technology company and portfolio company of nference, announced…

2 hours ago

Fabric Acquires MeMD, Expanding Virtual Care Services to 30,000 Employers and 5 Million Members

AI-powered clinical intelligence, seamless journey automation, and a robust network of behavioral health and medical…

2 hours ago

Movano Health Announces Dr. Fatima Rodriguez Joining July 11 Virtual Event

Allele Capitals' Matt Hughes will moderate future forward panel on enterprise need in wearables for…

2 hours ago

Aspen Laser and TheraLight Complete Corporate and Warehouse Expansion

Recent expansion adds 7,500 square feet to the companies' headquarters LINDON, Utah, June 28, 2024…

2 hours ago

Breakthrough in Tremor Treatment: Robotic Therapy Developed by GIST Researchers Improves Daily Activities

Introducing SPINDLE, a pioneering robotic rehabilitation system to enhance daily living activities for individuals with…

2 hours ago